GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements
Executive Summary
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
You may also be interested in...
Growing Complex Generic Application Load May Force US FDA Staffing Changes
Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.
US Industry Welcomes Nomination Of Califf To FDA Helm For A Second Time
The US off-patent industry has welcomed the news that Robert Califf looks likely to serve a second term as US Food and Drug Administration commissioner, after his nomination by US President Joe Biden.
Growing Complex Generic Application Load May Force US FDA Staffing Changes
Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.